


### Remarks

The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has also been added as a separate sheet, and should be inserted following the claims in the specification.

The cancellation of claims 11-2, 20-21 and 26-27 are to reduce the number of claims for prosecution. The amendments to the claim 40 are to eliminate multiple dependencies and to place the claims in proper format. No new matter has been added.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346  
Encl.: Abstract

  
John T. Prince  
Attorney for Applicant  
Reg. No. 43,019

Date: February 10, 2006